Literature DB >> 17080910

Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus.

C P Chung1, A Oeser, I Avalos, P Raggi, C M Stein.   

Abstract

The Framingham risk score is widely used to identify patients at increased cardiovascular risk, and women with systemic lupus erythematosus (SLE) have a marked increased prevalence of cardiovascular events. Thus, we examined the hypothesis that cardiovascular risk scores would identify women with SLE who had asymptomatic coronary atherosclerosis. Ninety-three women with SLE and 65 control subjects were studied. The Framingham score and a score for younger populations developed from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study were compared in both groups. Coronary atherosclerosis was ascertained by electron beam computed tomography. There were no significant differences in the median (interquartile range) Framingham [5 (2-10) compared to 7 (0-10), P = 0.88] and PDAY [15 (14-18) compared to 16 (13-18), P = 0.99] scores in patients with SLE and controls, respectively. Coronary atherosclerosis was associated with higher Framingham [12 (3-15) compared to 4 (1-8), P = 0.008] and PDAY [17 (15-19 compared to 15 (12-18), P = 0.03)] scores in patients with SLE; however, 99% of patients were classified as low-risk with a 10-year predicted risk of 1% (<1-3%). Our data indicate that cardiovascular risk scores are not adequate for risk stratification in women with SLE. Measurement of coronary calcification may add information to identify asymptomatic women with lupus who might benefit from aggressive preventive measures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080910     DOI: 10.1177/0961203306071870

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

1.  Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus.

Authors:  R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

2.  Epicardial adipose tissue is increased in patients with systemic lupus erythematosus.

Authors:  Aliza Lipson; Nikolaos Alexopoulos; Gregory Randell Hartlage; Chesnal Arepalli; Annette Oeser; Aihua Bian; Tebeb Gebretsadik; Ayumi Shintani; Arthur E Stillman; C Michael Stein; Paolo Raggi
Journal:  Atherosclerosis       Date:  2012-06-17       Impact factor: 5.162

Review 3.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

4.  Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites.

Authors:  Roksana Karim; Howard N Hodis; Robert Detrano; Chao-Ran Liu; Chi-Hua Liu; Wendy J Mack
Journal:  Am J Cardiol       Date:  2008-07-10       Impact factor: 2.778

Review 5.  Ischemic heart disease in women: a focus on risk factors.

Authors:  Puja K Mehta; Janet Wei; Nanette K Wenger
Journal:  Trends Cardiovasc Med       Date:  2014-10-16       Impact factor: 6.677

Review 6.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

7.  Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort.

Authors:  Vaneet K Sandhu; Janet Wei; Louise E J Thomson; Daniel S Berman; Jay Schapira; Daniel Wallace; Michael H Weisman; C Noel Bairey Merz; Mariko L Ishimori
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-06-04       Impact factor: 4.794

8.  Association between Framingham risk score and subclinical atherosclerosis among elderly with both type 2 diabetes mellitus and healthy subjects.

Authors:  Moatassem S Amer; Mohamed S Khater; Omar H Omar; Randa A Mabrouk; Shimaa A Mostafa
Journal:  Am J Cardiovasc Dis       Date:  2014-01-15

9.  Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus.

Authors:  M J Ormseth; L L Swift; S Fazio; M F Linton; P Raggi; J F Solus; A Oeser; A Bian; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2012-10-11       Impact factor: 2.911

10.  Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors.

Authors:  Young Hee Rho; Annette Oeser; Cecilia P Chung; Jason D Morrow; C Michael Stein
Journal:  Arch Drug Inf       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.